Tracking Resistance to Artemisinin Collaboration (TRAC)

TRAC is investigating the scope and spread of parasite resistance to artemisinin-based therapies at sites across Asia and Africa. The first TRAC study has been completed. This multi-centre, open-label randomised trial studied the clearance rates of peripheral blood P. falciparum parasitaemias in patients with acute uncomplicated falciparum malaria treated with two different doses of artesunate. Findings were used to validate the recently discovered kelch13 marker of artemisinin resistance. Working with MalariaGEN, TRAC samples have been sequenced and analysed for features of population genetics and signatures of selection, and contributed to the genetic basis of a genome-wide associations study for genetic markers of artemisinin resistance. Where samples were found to contain P. vivax data, for example due to mixed infection, this data was contributed to the P. vivax Genome Variation project.

Summary

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Locations

Attapeu

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Bago

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Binh Phuoc

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Chittagong

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Kachin

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Kinshasa

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Kwara

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Mandalay

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Pailin

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Preah Vihear

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Pursat

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Ranong

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Ratanakiri

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Sisakhet

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers

Tak

Samples/Year

QC Pass

Samples that passed Whole-Genome Sequencing Quality Control (QC)

Resistance

Predicted resistance status for main antimalarial drug treatments from molecular markers